Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.82 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | AGER | Q15109 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008337 | 0.91 | MAPT (1.00) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL12070564 | 0.84 | FFAR1 (0.61) | MAPTMCOLN3CA12CA9FFAR1 | |
| SCHEMBL15374351 | 0.84 | FFAR1 (0.61) | MAPTMCOLN3CA12CA9FFAR1 | |
| SCHEMBL9201669 | 0.84 | FFAR1 (0.61) | MAPTMCOLN3CA12CA9FFAR1 | |
| SCHEMBL14469933 | 0.84 | FFAR1 (0.74) | MAPTMCOLN3CA12CA9FFAR1 | |
| SCHEMBL10186890 | 0.84 | FFAR1 (0.74) | MAPTMCOLN3CA12CA9FFAR1 | |
| SCHEMBL24125059 | 0.82 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL18031174 | 0.82 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL6828479 | 0.82 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA | |
| SCHEMBL17174235 | 0.82 | MAPT (0.82) | MAPTMCOLN3CA12CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023938-A1 | Sulfonamide derivatives | TABUCHI TAKANORI (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6586617-B1 | Nontoxic microbiocides such as 4'-chloro-N-ethyl-2'-nitro-p-toluenesulfonanilide, for agricultural or horticultural, prepared by alkylation or nitration | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1174028-A1 | SULFONAMIDE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023938-A1 | Sulfonamide derivatives | FPR1, MRM1, SULT1E1 | MAPT 4869/4885MCOLN3 3672/4885CA12 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.